drugset
drugset / Trial / NCT01629329

Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine

NCT01629329 ↗

Phase 4 Terminated 93 enrolled Albert Einstein Healthcare Network
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this randomized, double blind study is to demonstrate that one dose oral "excedrin migraine" (acetaminophen, aspirin and caffeine) is not inferior when compared to one dose of intravenous prochlorperazine for the treatment of acute migraine headaches in the emergency department.

Timeline

Start
2010-11
Primary completion
2014-04
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetaminophen Small molecule 500 mg Oral
Comparator Aspirin Small molecule 500 mg Oral
Comparator Caffeine Small molecule 130 mg Oral
Comparator Prochlorperazine Small molecule 10 mg Intravenous

Indications

migraine disorder